- 1. (+-)-Verapamil hydrochloride
- [The hydrochloride form of Verapamil, which is a phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04) ( NCI )] (UMLS (NCI) C0700468) =Organic Chemical; Pharmacologic Substance =alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile;
=VERAPAMIL HYDROCHLORIDE 120 MG;
VERAPAMIL HYDROCHLORIDE 180 MG;
VERAPAMIL HYDROCHLORIDE 240 MG;
VERAPAMIL HYDROCHLORIDE 40 MG;
VERAPAMIL HYDROCHLORIDE 80 MG;
VERAPAMIL HYDROCHLORIDE 2.5 MG/ML;
VERAPAMIL HYDROCHLORIDE 360 MG;
VERAPAMIL HYDROCHLORIDE 200 MG;
VERAPAMIL HYDROCHLORIDE 100 MG;
| - 51. Vaccine-Sensitized Draining Lymph Node Cells
- [Cells isolated from lymph nodes from patients, and activated in vitro to generate tumor-specific effector T cells. Lymph nodes in the lymphatics draining tumors often contain T cells that are immunologically sensitized but functionally deficient. Vaccine-sensitized draining lymph node cells are prepared by isolating these lymphocytes in vitro and stimulating them with cytokines to differentiate into mature effector cells. Vaccine-draining lymph node cells may also be produced by pharmacological activation of lymph node-derived lymphocytes with drugs such as ionomycin or with bacterial toxin; these activated lymphocytes may be expanded in culture with cytokines such as interleukin-2 prior to infusion into the patient. (NCI04) ( NCI )] (UMLS (NCI) C0879357) VDLN Cells =Cell ;
|
- 2. *Velocity
- (UMLS (HL7) C1547053) =Quantitative Concept =Kind of quantity;
| - 52. VaccineManufacturer
- [The manufacturer of a vaccine. ( HL7V3.0 )] (UMLS (HL7) C1553793) =Intellectual Product =CodeSystem;
=Alpha Therapeutic Corporation;
Aviron;
Chiron Corporation;
Greer Laboratories, Inc.;
Immuno International AG;
Immuno-U.S., Inc.;
Korea Green Cross Corporation;
Massachusetts Public Health Biologic Laboratories;
MedImmune, Inc.;
Merck & Co., Inc.;
North American Vaccine, Inc.;
New York Blood Center;
Organon Teknika Corporation;
Sclavo, Inc.;
Abbott Laboratories (includes Ross Products Division);
Adams Laboratories;
Armour [Inactive - use CEN];
More… |
- 3. *Velocity Ratio
- (UMLS (HL7) C1547054) =Quantitative Concept =Kind of quantity;
| - 53. Vaccines administered (code = CVX)(parenteral, unless oral is noted)
- (UMLS (HL7) C1547693) =Pharmacologic Substance; Immunologic Factor =HL7 Vocabulary Version 2.5;
=Bacille Calmette-Guerin Live;
botulinum antitoxin;
cholera;
diphtheria antitoxin;
DTP;
[IM500] IMMUNOGLOBULINS;
flu vaccine;
measles;
mumps;
pertussis;
plague;
OPV;
RABIES VACCINE;
rubella;
smallpox;
TETANUS TOXOID;
TYPHOID VACCINE;
leprosy;
CMVIG;
HBIG;
Hep B, NOS;
MMR;
MMRV;
Chickenpox Vaccine;
VARICELLA ZOSTER IMMUNE GLOBULIN;
GLOBULIN,IMMUNE (IV);
HIV;
meningococcal;
Hep A, More… |
- 4. *Viscosity
- (UMLS (HL7) C1547055) =Quantitative Concept =Kind of quantity;
| - 54. VaccineType
- [The kind of vaccine. ( HL7V3.0 )] (UMLS (HL7) C1554000) =Intellectual Product =CodeSystem;
=Bacille Calmette-Guerin Live;
botulinum antitoxin;
cholera;
diphtheria antitoxin;
DTP;
[IM500] IMMUNOGLOBULINS;
flu vaccine;
measles;
mumps;
pertussis;
plague;
OPV;
RABIES VACCINE;
rubella;
smallpox;
TETANUS TOXOID;
TYPHOID VACCINE;
leprosy;
CMVIG;
HBIG;
Hep B, NOS;
MMR;
MMRV;
Chickenpox Vaccine;
VARICELLA ZOSTER IMMUNE GLOBULIN;
GLOBULIN,IMMUNE (IV);
HIV;
meningococcal;
Hep More… |
- 5. *Volume
- [The amount of three dimensional space occupied by an object or the capacity of a space or container. ( NCI )] (UMLS (HL7) C0449468) =Quantitative Concept =Kind of quantity;
| - 55. vaccinia immune globulin
- [vaccinia immune globulin ( HL7V3.0 )] (UMLS (HL7) C1548487) =Organic Chemical; Pharmacologic Substance; Immunologic Factor =Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType |
- 6. *Volume Content
- (UMLS (HL7) C1264660) =Quantitative Concept =Kind of quantity;
| - 56. Vaccinia-MUC-1 Vaccine/Vaccinia-TRICOM Vaccine
- (UMLS (NCI) C1328073) =Therapeutic or Preventive Procedure ;
|
- 7. *Volume Fraction
- [Quotient of the volume of a component and the total volume of the system containing the component. For clinical chemistry the term component is recommended, IS0 uses substance. For clinical chemistry the term system is recommended, IS0 uses mixture. ( NCI )] (UMLS (HL7) C1264666) ;
Volume Fraction =Quantitative Concept =Kind of quantity;
| - 57. Vaccinia-Prostate-Specific Antigen-TRICOM Vaccine
- [A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA. ( NCI )] (UMLS (NCI) C1327973) Vaccinia-PSA-TRICOM Vaccine =Pharmacologic Substance; Immunologic Factor
|
- 8. *Volume Rate
- (UMLS (HL7) C1264672) =Quantitative Concept =Kind of quantity;
| - 58. VaccinOvar
- (UMLS (NCI) C1328701) =Pharmacologic Substance; Immunologic Factor ;
|
- 9. *Volume Ratio
- (UMLS (HL7) C1547056) =Quantitative Concept =Kind of quantity;
| - 59. Vacuolar
- [Any membrane-enclosed spaces or cavities within a cell. ( NCI )] (UMLS (NCI) C0042219) =Cell Component
|
- 10. V
- [The SI derived unit of electric potential and electromotive force, equal to the difference of electric potential between two points on a conducting wire carrying a constant current of one ampere when the power dissipated between the points is one watt, equivalent to the potential difference across a resistance of one ohm when one ampere of current flows through it. ( NCI )] (UMLS (NCI) C0439502) =Quantitative Concept =UnitOfMeasureAtomInsens;
UnitOfMeasureAtomSens | - 60. VACUUM EXT DEL W EPISIOT
- [ ] (UMLS (ICD9CM) C0177270) =Therapeutic or Preventive Procedure
|
- 11. V (voltage)
- [ ] (UMLS (CSP) C0598352) =Quantitative Concept ;
| - 61. Vacuum extraction
- [Removal of the fetus from the uterus or vagina at or near the end of pregnancy with a metal traction cup that is attached to the fetus' head. Negative pressure is applied and traction is made on a chain passed through the suction tube. (From Stedman, 26th ed & Dorland, 28th ed) ( MSH )] (UMLS (ICD9CM) C0042225) =Therapeutic or Preventive Procedure
|
- 12. V element
- [metallic element with atomic symbol V, atomic number 23. ( CSP )] (UMLS (CSP) C0042306) =Biologically Active Substance; Hazardous or Poisonous Substance; Element, Ion, or Isotope =Micronutrient;
heavy metal;
Unclassified Ingredient Preparations;
=VANADIUM 10 MCG | - 62. VAD (ventricular assist device)
- [ ] (UMLS (CSP) C1456081) =Medical Device
|
- 13. v erbB
- [ ] (UMLS (CSP) C0242983) =Gene or Genome ;
| - 63. VAG RECONST W GRFT/PROS
- [ ] (UMLS (ICD9CM) C1955500) Vaginal reconstruction with graft or prosthesis;
=Therapeutic or Preventive Procedure |
- 14. v fes
- [ ] (UMLS (CSP) C0599868) =Gene or Genome ;
| - 64. VAG REPAIR INVERS UTERUS
- [ ] (UMLS (ICD9CM) C0177210) =Therapeutic or Preventive Procedure
|
- 15. v fms
- [ ] (UMLS (CSP) C0080282) =Gene or Genome ;
| - 65. VAG SUSP/FIX W GRFT/PROS
- [ ] (UMLS (ICD9CM) C1955501) Vaginal suspension and fixation with graft or prosthesis;
=Therapeutic or Preventive Procedure |
- 16. v fps
- [ ] (UMLS (CSP) C0599869) =Gene or Genome ;
| - 66. vagina disorder
- [deviation from or interruption of the normal structure or function of the vagina. ( CSP )] (UMLS (CSP) C0042251) =Disease or Syndrome =FEMALE GENITAL DIS NOS;
Female Reproductive System Disease =Neoplasm of the Vagina;
vaginitis;
Hematocolpos;
Vaginal Fistula;
Neoplasm of the Vagina;
vaginitis;
Discharge, vaginal;
CANDIDAL VULVOVAGINITIS;
Dyspareunia;
|
- 17. v H ras
- [ ] (UMLS (CSP) C0080286) =Gene or Genome ;
| - 67. Vagina hemorrhage
- (UMLS (NCI) C0151706) =Finding =HEMORRHAGIC COND NOS;
Pregnancy Complication;
Discharge, vaginal;
|
- 18. v jun
- [ ] (UMLS (CSP) C0087142) =Gene or Genome
| - 68. Vagina Verrucous Carcinoma
- (UMLS (NCI) C1336944) Vagina Verrucous Squamous Cell Carcinoma;
Vaginal Verrucous Carcinoma;
Vaginal Verrucous Squamous Cell Carcinoma;
Verrucous Carcinoma of the Vagina;
Verrucous Carcinoma of Vagina;
Verrucous Squamous Cell Carcinoma of the Vagina;
Verrucous Squamous Cell Carcinoma of Vagina;
=Neoplastic Process |
- 19. v K ras
- [ ] (UMLS (CSP) C0080289) =Gene or Genome ;
| - 69. Vaginal Abscess
- (UMLS (NCI) C0750053) =Disease or Syndrome
|
- 20. v mos
- [ ] (UMLS (CSP) C0080293) =Gene or Genome ;
| - 70. VAGINAL BIOPSY
- [Removal of tissue from the vagina for microscopic examination. ( NCI )] (UMLS (ICD9CM) C0195133) =Diagnostic Procedure
|
- 21. v myc
- [ ] (UMLS (CSP) C0080295) =Gene or Genome ;
| - 71. VAGINAL CONST W GRF/PROS
- [ ] (UMLS (ICD9CM) C1955499) Vaginal construction with graft or prosthesis;
=Therapeutic or Preventive Procedure |
- 22. v src
- [A tyrosine-specific protein kinase encoded by the v-src oncogene of Rous sarcoma virus. The transforming activity of pp60(v-src) depends on both the lack of a critical carboxy-terminal tyrosine phosphorylation site at position 527, and the attachment of pp60(v-src) to the plasma membrane which is accomplished by myristylation of its N-terminal glycine. ( MSH )] (UMLS (CSP) C0029009) =Amino Acid, Peptide, or Protein; Enzyme ;
| - 72. VAGINAL CONSTRUCTION
- (UMLS (ICD9CM) C1377996) =Therapeutic or Preventive Procedure
|
- 23. V-gas
- [ ] (UMLS (CSP) C1113683) =Organic Chemical; Hazardous or Poisonous Substance
| - 73. Vaginal construction and reconstruction
- [ ] (UMLS (ICD9CM) C0177232) =Therapeutic or Preventive Procedure
|
- 24. V-Rasha
- [V-Ras-Ha is a transforming protein encoded by the v-Ras-Ha oncogene (or v-Ha-Ras) of Harvey murine sarcoma virus (Ha-MuSV). ( NCI )] (UMLS (NCI) C1336923) V-Ras-Ha =Gene or Genome
| - 74. Vaginal Cream
- (UMLS (HL7) C0042238) =Biomedical or Dental Material =CREAM;
=Vaginal Cream with Applicator;
|
- 25. v-sis Platelet Derived Growth Factor, Beta Polypeptide
- [v-sis Platelet Derived Growth Factor beta polypeptide is the viral homologue of PDGFB. Viral oncogenes originate from normal cellular genes by recombination between a parent nontransforming virus and host cellular DNA; the cellular genes often code for important functions in cell growth or tissue differentiation. PDGF is the major serum polypeptide mitogen for cells of mesenchymal origin and has two dissimilar subunits, A and B. The B chain has homology to SIS and is alone sufficient for mitogenesis. Most proliferating cells are programmed to undergo apoptosis unless specific survival signals are provided. PDGF promotes proliferation and inhibits apoptosis by activating the RAS/PIK3/AKT1/IKK/NFKB1 pathway, inducing putative anti-apoptotic genes. (from OMIM 190040 and NCI) ( NCI )] (UMLS (NCI) C1337057) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 75. Vaginal Cuff
- (UMLS (HL7) C1550321) =Body Part, Organ, or Organ Component =Body Part;
|
- 26. v-Yes-1 Yamaguchi Sarcoma Viral Oncogene Homolog 1 Gene
- [This gene plays a role in the formation of intercellular junctions. ( NCI )] (UMLS (NCI) C0919479) YES1;
YES1 Gene;
=Gene or Genome ;
| - 76. Vaginal discharge
- [A common gynecologic disorder characterized by an abnormal, nonbloody discharge from the genital tract.(MSH)] (UMLS (ICPC) C0227791) (Vaginal discharge; MAGINA JARIOA (ESKL. ODOLJARIOA); Vaginalt udflad; Vaginale afscheiding; VUOTO EMATTIMESTA; Ecoulement vaginal; vaginaler Ausfluss; hafrasha mehanartik; huvely-folyas; Perdite vaginali; UTFLOD FRA SKJEDEN; Secrecao vaginal; Secrecion vaginal; FLYTNING) Vaginal discharge =Disease or Syndrome =vagina disorder; FEMALE GENITAL SYSTEM (INCLUDING BREAST); Symptoms and Complaints Component; =Leukorrhea; Vagina hemorrhage;
|
- 27. V0
- [No evidence of venous invasion, in accordance with TNM classification system guidelines. (from AJCC 6th Ed.) ( NCI )] (UMLS (NCI) C0441906) =Finding
| - 77. VAGINAL DOUCHE
- [The washing of the VAGINA cavity or surface with a solution. Agents or drugs can be added to the irrigation solution. ( MSH )] (UMLS (ICD9CM) C0204785) =Therapeutic or Preventive Procedure
|
- 28. V01
- (UMLS (HL7) C1549927) =Intellectual Product =Message structure;
| - 78. Vaginal Endodermal Sinus Neoplasm
- (UMLS (NCI) C1336945) Vaginal Endodermal Sinus Tumor;
Vaginal Yolk Sac Neoplasm;
Vaginal Yolk Sac Tumor;
=Neoplastic Process ;
|
- 29. V02
- (UMLS (HL7) C1549930) =Intellectual Product =Message structure;
| - 79. VAGINAL ENTEROCELE
- [An intestinal HERNIA. ( MSH )] (UMLS (ICD9CM) C0205792) =Disease or Syndrome; Anatomical Abnormality
|
- 30. V03
- (UMLS (HL7) C1549928) =Intellectual Product =Message structure;
| - 80. vaginal fluid
- [ ] (UMLS (CSP) C0392908) =Body Substance ;
|
- 31. V04
- (UMLS (HL7) C1549929) =Intellectual Product =Message structure;
| - 81. Vaginal foam with applicator
- (UMLS (HL7) C1373239) =Biomedical or Dental Material =Vaginal foam;
|
- 32. V1
- (UMLS (NCI) C0457422) =Finding
| - 82. Vaginal Fornix
- (UMLS (NCI) C0227794) =Body Location or Region
|
- 33. V2
- (UMLS (NCI) C0457423) =Finding
| - 83. Vaginal Gel
- (UMLS (HL7) C0042257) =Biomedical or Dental Material =GEL;
=Vaginal Gel with Applicator;
|
- 34. VA
- (UMLS (HL7) C1611840) =Intellectual Product ;
=Clinic/Center;
| - 84. Vaginal Gel with Applicator
- (UMLS (HL7) C1553201) =Biomedical or Dental Material =Vaginal Gel;
|
- 35. VA
- [The first branch of the SUBCLAVIAN ARTERY with distribution to muscles of the NECK; VERTEBRAE; SPINAL CORD; CEREBELLUM; and interior of the CEREBRUM. ( MSH )] (UMLS (NCI) C0042559) =Body Part, Organ, or Organ Component ◊ [A state in the mid-atlantic United States. Its capital is Richmond. ( NCI )] (UMLS (NCI) C0042753) Geographic Area ;
| - 85. VAGINAL HEMATOMA
- (UMLS (ICD9CM) C0156389) =Injury or Poisoning
|
- 36. vacation home
- [A vacation home, to reach a person while on vacation. ( HL7V3.0 )] (UMLS (HL7) C1550702) =Spatial Concept =home address;
| - 86. Vaginal Itching
- (UMLS (NCI) C0042256) =Sign or Symptom
|
- 37. Vacation Home Number
- (UMLS (HL7) C1549670) =Intellectual Product =Telecommunication use code;
| - 87. Vaginal Mass
- (UMLS (NCI) C0221783) =Finding ;
|
- 38. Vacation Supply
- [Supply date is due to patient vacation ( HL7V3.0 )] (UMLS (HL7) C1555303) =Intellectual Product =Supply Appropriate;
| - 88. Vaginal Metastatic Adenocarcinoma
- (UMLS (NCI) C0862601) =Neoplastic Process
|
- 39. vaccination
- [Treatment with a vaccine. ( NCI )] (UMLS (NCI) C0042196) =Therapeutic or Preventive Procedure ;
| - 89. Vaginal Non-Neoplastic Disease
- (UMLS (NCI) C1336941) Vaginal Non-Neoplastic Disorder;
=Disease or Syndrome |
- 40. Vaccination against yellow fever
- [ ] (UMLS (ICD9CM) C0199823) =Therapeutic or Preventive Procedure
| - 90. VAGINAL PACKING
- (UMLS (ICD9CM) C1270937) =Therapeutic or Preventive Procedure
|
- 41. Vaccination not carried out
- [ ] (UMLS (ICD9CM) C1561700) =Finding
| - 91. VAGINAL RECONSTRUCTION
- (UMLS (ICD9CM) C0195196) =Therapeutic or Preventive Procedure
|
- 42. Vaccination record response
- (UMLS (HL7) C1548130) =Idea or Concept =Message type;
| - 92. Vaginal Stricture
- (UMLS (NCI) C0269208) =Disease or Syndrome
|
- 43. Vaccine
- [A Type of medicine that creates an immune protection without the recipient experiencing the disease. ( HL7V3.0 )] (UMLS (HL7) C1552558) =Intellectual Product ;
=MaterialEntityClassType;
| - 93. Vaginal Suppository
- (UMLS (HL7) C1136199) =Biomedical or Dental Material =SUPP;
|
- 44. vaccine delivery
- [ ] (UMLS (CSP) C1331096) =Health Care Activity
| - 94. VAGINAL SUSPENS & FIXAT
- [ ] (UMLS (ICD9CM) C1261299) Vaginal suspension and fixation =Therapeutic or Preventive Procedure
|
- 45. vaccine development
- [development of prophylactic preparation which is given to produce immunity to pathogenic organisms or neoplasms. ( CSP )] (UMLS (CSP) C0597634) =Research Activity ;
=immunologic substance development/preparation;
| - 95. Vaginal Tablet
- (UMLS (HL7) C0042264) =Biomedical or Dental Material =TAB;
|
- 46. vaccine evaluation
- [any process by which immunogenicity, immune response, toxicity, metabolism, absorption, preferred route of administration, safe dosage range, etc., for a vaccine or group of vaccines is determined through assessment in humans, animals or cells. ( CSP )] (UMLS (CSP) C1171370) vaccine screening;
vaccine testing =Research Activity ;
=evaluation/testing;
| - 96. Vaginal Vault
- (UMLS (HL7) C0549115) =Body Part, Organ, or Organ Component =Body Part;
|
- 47. vaccine evaluation center
- [ ] (UMLS (CSP) C1328964) =Manufactured Object; Health Care Related Organization
| - 97. VaginalRoute
- [Vaginal ( HL7V3.0 )] (UMLS (HL7) C0205537) =Functional Concept =RouteBySite;
=Douche, vaginal;
Insertion, vaginal;
Topical application, vaginal;
|
- 48. Vaccine Information
- (UMLS (HL7) C1546482) =Idea or Concept =What subject filter;
| - 98. VAGINISMUS
- (UMLS (ICD9CM) C0546846) =Disease or Syndrome ;
|
- 49. Vaccine Therapy
- [Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system. ( NCI )] (UMLS (NCI) C0042209) =Therapeutic or Preventive Procedure
| - 99. vaginitis
- [inflammation of the vagina characterized by pain and a purulent discharge. ( CSP )] (UMLS (CSP) C0042267) =Disease or Syndrome =vagina disorder;
=TRICHOMONAL VAGINITIS;
Vulvovaginitis;
Vaginosis, Bacterial;
Atrophic Vaginitis |
- 50. Vaccine-Draining Lymph Node Lymphocyte Therapy
- (UMLS (NCI) C0879364) =Therapeutic or Preventive Procedure ;
| - 100. Vaginitis and vulvovaginitis
- (UMLS (ICD9CM) C0042268) =Disease or Syndrome
|
home
